Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years

Table 3 Laboratory findings of the patients with intrahepatic sarcomatoid cholangiocarcinoma

Case	CEA (ng/mL)	CA19-9 (U/mL)	AFP (ng/mL)	PIVKA-II (mAU/mL)	AST (U/L)	ALT (U/L)	TB (mg/dL)	DB (mg/dL)	ALP (U/L)	GGT (U/L)
1	0.74	> 1200.00	131.67	69	25	19	1.0	0.4	387	115
2	1.45	3.38	66.45	16	31	10	0.7	0.2	252	32
3	0.10	3.00	2.54	35	54	96	0.4	0.2	892	137
4	2.35	1809.57	1.73	N/A	42	30	0.9	0.6	1385	N/A
5	1.81	2.33	2.31	20	43	57	1.0	0.6	1520	203
6	12.70	710.38	3.92	N/A	23	39	0.7	0.3	1133	253
7	1.18	12.59	2.70	20	23	16	0.6	0.4	638	224
8	3.15	> 1200.00	1.71	N/A	30	31	1.1	0.6	757	323
9	1.08	< 2.00	1.52	N/A	80	30	0.7	0.5	476	98
10	3.56	599.14	1.02	N/A	37	47	1.1	0.8	804	N/A
11	1.81	5.77	3.02	14	34	36	0.3	0.1	369	35

AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; DB: Direct bilirubin; GGT: Gamma-glutamyl transferase; N/A: Not applicable; PIVKA-II: Protein-induced by vitamin K antagonist-II; TB: Total bilirubin.